Neuropathy is common in the diabetic population, affecting approximately 50% of patients with long-lasting diseases. The most common type is symmetric distal sensorimotor polyneuropathy, in which pain is a dominant symptom.
Although painful neuropathy responds to antidepressants, anticonvulsants and opioid agonists, these drugs are often ineffective or can induce severe adverse effects. Hence, to manage this condition effectively, we need to seek other safe and effective therapeutic options.
Invasive neurostimulation techniques are already used successfully to treat drug-resistant neuropathic pain, including brain stimulation and epidural motor cortex stimulation.
Brainsway* Deep TMS therapy, or Deep Transcranial Magnetic Stimulation, offers an effective*, safe, non-invasive treatment for chronic pain. Brainsway Deep TMS therapy performs magnetic stimulation of brain structures and networks related to chronic pain and brings significant improvement to patients. It is an outpatient procedure which does not require hospitalization or anesthesia, well tolerated and entails no systemic side effects*.
Deep TMS therapy is a non-surgical technique that can modulate cortical excitability and inhibit pain perception in the human brain noninvasively.
Standard TMS coils (such as the figure-of-eight coil) permit stimulation of only superficial cortical regions of the human brain, because the higher stimulus intensities required to affect deeper brain areas increase the risk of adverse effects. Brainsway's H-coil allows brain stimulation without significantly increasing the intensity of induced fields in superficial cortical regions. The H-coil can therefore be used to stimulate the lower-limb motor cortex, an area that lies in interior sections of the motor area, tucked deep in the medial longitudinal fissure.
A recent study used Deep TMS over the deeper leg motor cortex to treat patients suffering from diabetic neuropathic pain (see link below). Twenty-five patients were enrolled and treated with the HMMC-coil, which is designed for effective activation of neuronal structures in the motor cortex, including the deeper structures of the leg motor cortex, with hemispheric symmetry. Patients were randomly assigned to receive daily active or sham Deep TMS for 5 consecutive days. Sham/active treatment sessions were applied in crossover design with intervals of 5 weeks.
The analgesic effect of Deep TMS therapy (real vs. sham) was evaluated by measurements of visual analogue scale (VAS) and the nociceptive flexion RIII reflex.
Repeated measures ANOVA showed a significant decrease subjective pain sensation (as measured by the VAS) in the active but not the sham group (p=0.01); and in RIII reflex threshold (p<0.01) following active but not sham treatments. The improvements in both VAS scores and RIII reflex thresholds were preserved 3 weeks after the last active session.
Brainsway Deep TMS therapy is approved by the CE* and by ANIVISA for treating chronic pain.
IMPORTANT: Brainsway is at different stages of regulatory approval for different indications in different countries. While the status of our regulatory approvals is generally updated on this website, in order to verify whether Brainsway is currently approved for the treatment of this indication in your area, please contact us at firstname.lastname@example.org